Age at diagnosis for Duchenne muscular dystrophy: Why we must do better

Affiliations

Editorial

Rosaline Mary Quinlivan. Muscle Nerve. 2022 Aug.

. 2022 Aug;66(2):116-117.

doi: 10.1002/mus.27574. Epub 2022 Jun 6.

¹ Centre for Neuromuscular Diseases, UCL Institute of Neurology, National Hospital, London, UK.

No abstract available

Comment on

Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015.
Thomas S, Conway KM, Fapo O, Street N, Mathews KD, Mann JR, Romitti PA, Soim A, Westfield C, Fox DJ, Ciafaloni E; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Thomas S, et al. Muscle Nerve. 2022 Aug;66(2):193-197. doi: 10.1002/mus.27532. Epub 2022 Apr 11. Muscle Nerve. 2022. PMID: 35312090 Free PMC article.

1. Thomas S, Conway K, Fapo O, et al. Time to diagnosis of Duchenne Muscular Dystrophy remains unchanged: findings from the muscular dystrophy surveillance, tracking and research network (MDSTARnet) 2000-2015. Muscle Nerve. 2022;66:193-197.
1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93.
1. Eagle M, Baudouin S, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926-929.
1. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251-267.
1. Ricotti V, Ridout D, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84:698-705.